Blocking MEK signaling pathway could inhibit rhabdomyosarcoma growth

New CCR research shows that a form of a cancer that occurs mainly in children, embryonal rhabdomyosarcoma, which is driven by mutations to the RAS gene, may be susceptible to inhibition by drugs that target a pathway in which MEK protein signaling, triggered by RAS, plays an important role. This new mechanistic understanding of a complex biological process led the investigators to test a drug, trametinib, in mice implanted with the cancer. Their findings show that trametinib might be a good agent to test in clinical trials for this disease. Read more...

Blood cell

Activated platelets can promote tumor cell invasion into healthy tissue

Apr 19, 2018

Pre-clinical studies conducted by CCR investigators and colleagues show that platelets, tiny cells that promote blood clotting, when activated by the CD97 protein on the surface of tumor cells, enable the tumor cells to invade healthy tissue and then metastasize. The study, published April 17, 2018, in Cell Reports, was led by Kathleen Kelly, Ph.D., Chief, Laboratory of Genitourinary Cancer Pathogenesis. Read more...

Landmarks cover

New CCR publication, Landmarks, is now available

Apr 19, 2018

The Center for Cancer Research has been at the forefront of cancer research for decades. Spanning the spectrum from basic research to advances in clinical care, including the development of new cancer drugs and innovative vaccines, Landmarks highlights the remarkable discoveries that have occurred at CCR over the years.  Read more...

New CCR publication, Landmarks, is now available
Visual of mutations

Focusing on function to mine cancer genome data

Apr 17, 2018

CCR scientists have devised a strategy to sift through the tens of thousands of mutations in cancer genome data to find mutations that actually drive the disease. They have used the method to discover that the JNK signaling pathway, which in different contexts can either spur cancerous growth or rein it in, acts as a tumor suppressor in gastric cancers.  Read more...

Subgroups of DLBCL

Study led by Louis Staudt revises molecular classification for most common type of lymphoma

Apr 13, 2018

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. Though potentially curable, treatment does not eliminate the disease for all patients. A new study led by Louis Staudt, M.D., Co-Chief of the Lymphoid Malignancies Branch, identified genetic subtypes of DLBCL that could help explain why some patients respond to treatment whereas others do not.  Read more...

Study led by Louis Staudt revises molecular classification for most common type of lymphoma
leukemia cells

Phase I clinical trial will test multi-targeted immunotherapy in common childhood cancer

Apr 10, 2018

Chimeric antigen receptor (CAR) T-cell immunotherapy targeting the protein CD19 has shown promise in treating acute lymphoblastic leukemia (ALL). CD22-CAR T-cell therapy has yielded similarly encouraging results, but many patients relapse after either therapy. In an upcoming phase I clinical trial, Center for Cancer Research investigators will test a new strategy—treating patients with a CAR T-cell therapy that targets CD19 and CD22 simultaneously. Read more...

PC3 prostate cancer cells

Imaging technique predicts efficacy of targeting prostate tumor metabolism in mice

Apr 10, 2018

Disrupting glycolysis, a metabolic process tumors often rely on to feed their growth by partially breaking down sugars and not requiring oxygen, has emerged as a promising approach to treating metastatic prostate cancer in a study by Center for Cancer Research investigators.  Read more...

Marston Linehan

Marston Linehan featured in “The Code” video series from STAT and Retro Report

Apr 9, 2018

“Finding the Code: The Race to Sequence the Human Genome and What it Means” is the first in a three-part series from STAT and Retro Report investigating the roots of today’s most promising genetic technologies. Marston Linehan, Ph.D., Chief of the Urologic Oncology Branch, is featured for his work on the Human Genome Project.  Read more...

Marston Linehan featured in “The Code” video series from STAT and Retro Report
kidney tissue

Study reveals potentially prognostic gene, metabolism changes in kidney cancers

Apr 5, 2018

The Cancer Genome Atlas Research Network investigators, including CCR scientists, identified genetic and metabolic pathway changes linked to reduced survival of patients within and across subtypes of renal cell carcinoma (RCC), a type of kidney cancer. The study, published April 5, 2018, in Cell Reports, is part of The Cancer Genome Atlas (TCGA) Program, a joint effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). Read more...

Ovarian cancer

New clinical trial studies drug combination for recurring ovarian cancer

Apr 5, 2018

A new clinical trial is studying the effectiveness of an investigational drug combination that looks to see whether reducing the supply of oxygen to the cancer cells can make ovarian cancer shrink or slow its growth in association with an enzyme that repairs DNA damage. Read more...

immunotherapy research

New clinical trial tests prime-and-boost vaccine delivery for advanced solid tumors

Apr 3, 2018

Researchers are testing a prime-and-boost approach to safely direct the immune system to kill tumor cells that express brachyury, a protein expressed in high levels in some cancers. A new clinical trial is testing an experimental vaccine in patients whose cancers have not responded to standard treatments. Read more...

Pages